SG11202102432TA - Immunomodulators, compositions and methods there of - Google Patents
Immunomodulators, compositions and methods there ofInfo
- Publication number
- SG11202102432TA SG11202102432TA SG11202102432TA SG11202102432TA SG11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA
- Authority
- SG
- Singapore
- Prior art keywords
- immunomodulators
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018105582 | 2018-09-13 | ||
PCT/CN2019/105685 WO2020052650A1 (en) | 2018-09-13 | 2019-09-12 | Immunomodulators, compositions and methods there of |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102432TA true SG11202102432TA (en) | 2021-04-29 |
Family
ID=69776767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102432TA SG11202102432TA (en) | 2018-09-13 | 2019-09-12 | Immunomodulators, compositions and methods there of |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220041583A1 (en) |
EP (1) | EP3849972A4 (en) |
JP (1) | JP7453963B2 (en) |
KR (1) | KR20210061359A (en) |
CN (1) | CN112654617A (en) |
AU (1) | AU2019339703A1 (en) |
CA (1) | CA3112286A1 (en) |
EA (1) | EA202190766A1 (en) |
IL (1) | IL281164A (en) |
SG (1) | SG11202102432TA (en) |
WO (1) | WO2020052650A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210300909A1 (en) * | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3377488B1 (en) * | 2015-11-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2019530732A (en) * | 2016-08-03 | 2019-10-24 | アライジング・インターナショナル・インコーポレイテッドArising International, Inc. | Symmetric or semi-symmetrical compounds useful as immune modulators |
KR102599339B1 (en) * | 2016-12-20 | 2023-11-08 | 브리스톨-마이어스 스큅 컴퍼니 | Compounds useful as immunomodulators |
MD3558990T2 (en) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers |
JP7101678B2 (en) * | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | Heterocyclic compounds as immunomodulators |
WO2018119221A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
JOP20180040A1 (en) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
AU2019245288C1 (en) * | 2018-03-30 | 2024-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20210300909A1 (en) | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
AU2020214404A1 (en) * | 2019-01-31 | 2021-09-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
-
2019
- 2019-09-12 WO PCT/CN2019/105685 patent/WO2020052650A1/en unknown
- 2019-09-12 CN CN201980057938.8A patent/CN112654617A/en active Pending
- 2019-09-12 SG SG11202102432TA patent/SG11202102432TA/en unknown
- 2019-09-12 US US17/275,450 patent/US20220041583A1/en active Pending
- 2019-09-12 KR KR1020217010081A patent/KR20210061359A/en unknown
- 2019-09-12 EP EP19860432.4A patent/EP3849972A4/en active Pending
- 2019-09-12 AU AU2019339703A patent/AU2019339703A1/en active Pending
- 2019-09-12 JP JP2021513224A patent/JP7453963B2/en active Active
- 2019-09-12 EA EA202190766A patent/EA202190766A1/en unknown
- 2019-09-12 CA CA3112286A patent/CA3112286A1/en active Pending
-
2021
- 2021-03-01 IL IL281164A patent/IL281164A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3849972A4 (en) | 2022-06-01 |
CA3112286A1 (en) | 2020-03-19 |
IL281164A (en) | 2021-04-29 |
CN112654617A (en) | 2021-04-13 |
EP3849972A1 (en) | 2021-07-21 |
US20220041583A1 (en) | 2022-02-10 |
EA202190766A1 (en) | 2021-06-17 |
WO2020052650A1 (en) | 2020-03-19 |
KR20210061359A (en) | 2021-05-27 |
JP7453963B2 (en) | 2024-03-21 |
AU2019339703A1 (en) | 2021-04-08 |
JP2022511303A (en) | 2022-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285215A (en) | Immunomodulators, compositions and methods thereof | |
EP3774750A4 (en) | Immunomodulators, compositions and methods thereof | |
IL265045B1 (en) | Pd-1 homing endonuclease variants, compositions, and methods of use | |
ZA202007839B (en) | Polymerases, compositions, and methods of use | |
ZA202007838B (en) | Polymerases, compositions, and methods of use | |
IL280134A (en) | Anti-cd112r compositions and methods | |
IL268970A (en) | Novel compositions and methods | |
IL270776A (en) | Cblb endonuclease variants, compositions, and methods of use | |
GB201807325D0 (en) | Compositions and methods | |
EP3526334A4 (en) | Tgfbetar2 endonuclease variants, compositions, and methods of use | |
GB202201861D0 (en) | Novel methods and compositions | |
EP3504335A4 (en) | Tim3 homing endonuclease variants, compositions, and methods of use | |
IL280414A (en) | Bismuth-thiol compositions and methods of use | |
IL276135A (en) | Compositions and methods of use | |
SG11202104448WA (en) | Compositions and methods | |
GB2576614B (en) | Compositions, uses and methods | |
IL277786A (en) | Aav compositions, methods of making and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
GB201804163D0 (en) | Uses, compositions and methods | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
GB201817444D0 (en) | Methods and compositions | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
IL281164A (en) | Immunomodulators, compositions and methods there of | |
GB201819987D0 (en) | Methods and compositions | |
ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof |